Purpose: To compare outcomes among patients with localized esophageal and gastro-esophageal junction (GEJ) cancer who received concomitant chemo-radiation (CRT) using either cisplatin/5-FU or carboplatin/paclitaxel. CROSS trial demonstrated efficacy of carboplatin/paclitaxel in trimodality setting. However this regimen has also been adopted as an alternate for patients receiving CRT as definitive treatment due to better tolerance. Methods and Materials: Medical records of all patients diagnosed with localized carcinoma of esophagus and GEJ who underwent definitive CRT using cisplatin/5-FU, carboplatin/5-FU, or carboplatin/paclitaxel between January 2008 and March 2015 at our academic centre were reviewed. Results: Seventy-five patients (79% male) were identified with a median age of 74 years (range 45-86). Most (66%) had an adenocarcinoma and 37% squamous cell carcinoma. Sixty-three percent had distal 1/3rd and/or GEJ tumour. 48% received cisplatin/5-FU, 35% carboplatin/paclitaxel and 17% carboplatin/5-FU. Most patients (99%) received 50Gy in 25 fractions. The median overall survival (OS) for cisplatin/5-FU group was 27 months (m) (95%CI 17-39) with three-year OS of 42%, in contrast to 14 m (95%CI 11-17) and 13% among patients received carboplatin/paclitaxel (log-rank p = 0.006). The median OS for carboplatin/5-FU group was 17 m (95%CI 11-81) with three-year OS of 38%. Cisplatin/ 5-FU group had a significantly better distant metastasis free survival (median 20 versus 11 m, p = 0.04) when compared to carboplatin/paclitaxel group. On multivariate analysis, cisplatin/5-FU (hazard ratio(HR) 0.45, p = 0.023) and carboplatin/5-FU group (HR 0.46, p = 0.093) were found to be associated with OS adjusted for other patient, disease and treatment related characteristics.
Purpose: All studies to date have evaluated the dosimetric effect of bladder deformation using an organ model that includes the dose to the urine. This research reconstructed bladder dose using both hollow and solid organ models, to determine if dose/volume differences exist. Methods and Materials: Thirty-five prostate IMRT patients were selected, who had received 78 Gy in 39 fractions and full bladder instructions. Biomechanical modeling and finite element analysis was used to reconstruct bladder dose (solid and hollow organ model) using every third CBCT throughout the treatment course. Results: Reconstructed bladder dose was 11.3 Gy greater than the planned dose with a hollow model (p < 0.001) and 12.3Gy greater with a solid model (p < 0.0001). Median reconstructed volumes within the 30 Gy, 65 Gy and 78 Gy isodoses were 3-4 times larger with the solid bladder model (p < 0.0001). Using a solid bladder model resulted in a difference between planned and reconstructed dose that was 10% larger than when using a hollow model. The difference between planning bladder volume and median treatment volume was associated with the difference between the planned and reconstructed dose below 78 Gy (R2 > 0.61). Conclusions: Substantial differences exist between planned and reconstructed bladder dose, associated with the differences in bladder filling between planning and treatment. Dose reconstructed using a solid bladder model over-reports the volume of bladder within key isodose levels and overestimates the differences between planned and reconstructed dose. Dose reconstruction with a hollow organ model is recommended if the goal is to associate that dose with toxicity. Purpose: Follicular lymphoma (FL) is a progressive relapsing hematologic malignancy. At The Ottawa Hospital (TOH), autologous hematopoietic cell transplantation (AHCT) utilizing total body irradiation (TBI) has been used to treat relapsed FL patients for over 20 years. We reviewed our large single institution experience and assessed outcomes and late toxicity. Methods and Materials: We retrospectively reviewed consecutive patients undergoing AHCT for relapsed FL from July 1991 to February 2013. The pre-AHCT conditioning regimen was commonly Etoposide/Melphalan/TBI. Patients received TBI on a linear accelerator using a translating-bed technique. The total dose was 5 Gy/1fr for 92% of patients, the remainder received 12Gy/6fr. Lung attenuators were used to maintain dose homogeneity. Patient information was stored on our bone marrow transplant (BMT) database. Descriptive statistics were calculated for all relevant demographic variables. Overall survival was estimated from the BMT date using the Kaplan-Meier method. Second malignancies were reported. Late toxicity was assessed in patients with at least one year of follow up (FU). Lung, kidney and thyroid toxicity was evaluated through extensive chart reviews. Clinical toxicity, creatinine, PFTs, chest imaging, thyroid function tests were assessed pre-AHCT and post-AHCT. Results: We evaluated 174 patients with a median age of 50 years at transplant. There were 106 men and 68 women. Median follow up was 6.0 years. Median follow up among survivors was 8.3 years. Overall survival at one, five, 10 and 15 years was 93%, 73%, 57% and 47% respectively. Eighteen patients (10.3 %) developed a second malignancy; 11 (6.3%) had solid tumours, two (1.1%) had AML and five (2.9%) developed myelodysplastic syndrome. Median time to second malignancy was 7.2 years, with cumulative incidences of developing second cancer at 5% and 8% at five and 10 years. We evaluated 149 patients with at least one year of follow up. Of 80 assessable patients, 23% developed hypothyroidism; 3% were hypothyroid beforehand. Pre-AHCT, creatinine ranged from 41 to 139 umol/L. Post AHCT, at last FU, of 116 patients, creatinine (umol/L) was < 100 in 63%, 100-150 in 20%, 151-200 in 6% and > 200 in 9%. Hemodialysis was required for two patients. Clinical lung toxicity was noted in 6% of 95 patients. PFTs were recorded in 26 patients pre-AHCT and 46 patients post-AHCT. Abnormalities in DLCO were noted in 17% pre-AHCT and 26% of post-AHCT. Abnormalities in FEV1 were noted in 11% pre-AHCT and 25% of post-AHCT. Radiologic abnormalities were noted in 39%, with 23% being fibrotic changes, possibly radiation-induced, and 17% likely unrelated. Conclusions: Our results with TBI-based AHCT for relapsed FL are very good, with most patients surviving 10 years post-AHCT. Purpose: The use of 3D printing for medical use is well established and has been utilized in clinical practices ranging from surgical planning to individualized medical implants. Threedimensional printing has been implemented at our institution to create customized treatment accessories such as shielding and immobilization. In order to use 3D printing, the topography of the patient must first be acquired. We have previously achieved this using resource intensive methods such as a plaster mould or a CT scan. Recently, 3D scanners have been developed which are low cost (~$500), and can quickly acquire both the topographical and texture information of a patient. These scanners use methods such as structured light in order to construct accurate 3D models in minutes. We have characterized a structured light 3D scanner (3D Systems Sense), and have designed and built a scanning gantry in order to assess the clinical viability of this technology.
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Methods and Materials:
The gantry consists of a circular hoop formed from square aluminum tubing, with a diameter of 126.5 cm. The optical scanner is mounted to an arm that can be moved isocentrically along the circumference of the hoop. The scannerto-surface distance is adjustable to accommodate differently sized regions of the body. The gantry can tilt with respect to the patient table, allowing for acquisition of topography from virtually any direction. The gantry was built in-house with a total cost of about $500. An anthropomorphic head phantom was used to quantify the accuracy of the gantry-mounted 3D scanner. Meshes acquired using the 3D scanner were compared to a mesh generated from a high resolution CT scan, which was taken to be the gold standard. Optimal scan settings were identified and final assessment of the accuracy of the scanner was quantified using the Hausdorff distance between the two meshes. Results: The in-house gantry enabled quick and easy acquisition of patient topographical information with a low cost 3D scanner. Acquisition was much easier than using the scanner free-hand. The mean Hausdorff distance was typically found to be less than 0.5 mm, with maximum errors in the range of 1-2 mm. This was deemed to be clinically acceptable and the scanner has been used to design treatment accessories for several skin cancer patients. Conclusions: Through a collaborative and innovative approach, an optical scanner gantry has been developed which can quickly, easily and accurately acquire topographical information. This information can then be used to design customized treatment accessories for many different treatment sites and modalities, including bolus and immobilization for both photon and electron treatments and shielding for orthovoltage treatments. The gantry is very lightweight and easy to store.
CAN VMAT IMPROVE CONFORMALITY WHILE MAINTAINING KIDNEY DOSE FOR SEMINOMA PATIENTS
Tony Lam 1 , Andrew McPartlin 2 , Ali Hosni 2 , Tara Rosewall 2 , Padraig Warde 2 , Peter Chung 2 1 Princess Margaret Hospital, Toronto, ON 2 University of Toronto, Toronto, ON Purpose: To evaluate the use of VMAT planning techniques for para-aortic and ipsilateral pelvic irradiation in seminoma patients, driven by standard kidney contours and automatically generated concentric rings about the PTV. Material and Methods: Ten seminoma patients with small volume retroperitoneal nodes (< 5 cm) were randomly selected. CTV2 included the gross tumour plus a 5 mm margin, and CTV1 was contoured based on an expansion of blood vessels. PTV was defined by addition of 5 mm margin around the corresponding CTV, with PTV1 extending from 2 cm below the top of kidney to the top of femoral head, and modified to exclude both kidneys. The prescription dose (in 20 fractions) was 25 and 35 Gy for PTV1 and PTV2 respectively. Abdominal and pelvic organs at risk (OAR) were contoured. For each patient, a conformal (AP-PA, 18 MV) and VMAT (two 360-degree coplanar arcs, six MV, 15-degree collimator twist) plans were created. Dose constraints for the VMAT optimization were: Rt and Lt Kidney (D50% <350 cGy, max EUD < 350 cGy); RingPTV+2 cm (max dose = PTVmin), Normal tissue 4 cm beyond PTV (max dose < 1000 cGy, D50% < 150 cGy, D20% < 500 cGy). No other structures were included in the optimization. The maximum (D2%), mean (D50%) and minimum dose (D98%) for PTVs and OAR were obtained and compared between plans. Results: There was no difference in the coverage of PTV2, while VMAT provided better PTV1 coverage: mean D98% was 24.2 Gy +/-0.16 versus 23.9 Gy +/-0.25 (p = 0.05). Use of VMAT reduced the volume of normal tissue receiving 95% of the prescribed dose from 11% to 2%, compared to the conformal AP-PA plans (p = 0.005). Kidney D2% was reduced by 6Gy with VMAT (p = 0.03), while the kidney D50% was 1.3 Gy higher (p = 0.01). There was no significant difference in D2% or D50% for either heart or pancreas. VMAT reduced spinal cord dose: D2% (28.2 Gy +/-2.2 versus 32.2 Gy +/-4.4, p = 0.02) and D50% (12.6 Gy +/-8.7 versus 19.8 Gy +/-7.4, p = 0.01), and reduced the D2% for bone marrow (p = 0.01), large bowel (p = 0.05) and stomach (p = 0.05) but not for bladder or liver. Conversely, the conformal APPA resulted in lower D50% to bone marrow (p = 0.01), large bowel (p = 0.05), stomach (p = 0.01), bladder (p = 0.05) and liver (p = 0.05). Conclusions: It is possible to generate organ-sparing VMAT plans with only the kidneys and automatically generated concentric PTV rings included in the optimization process. Use of VMAT for para-aortic/pelvic irradiation improves the conformality of the isodoses to the PTV and reduces the maximum dose to the surrounding OAR, but at the cost of an increase in the low dose region. Purpose: Treatment of non-melanoma skin cancers of the face using ortho-voltage radiotherapy may require lead shielding to protect vulnerable organs at risk (OAR). As the human face has many complex and intricate contours, creating a lead shield can be difficult. The process can include creating a plaster mould of a patient's face to create the shield. It can be difficult or impossible for a patient who is claustrophobic or medically unable to lie flat to have a shield made by this technique. Other methods have their own shortcomings. We aimed to address some of these issues using an optical scanner and 3D printer technology. Methods and Materials: The clinicians identified three patients with skin cancer involving the nose who required treatment with low energy photons and would benefit from lead shielding. Marking was made on these patients to define the field. Optical images of these patients were acquired using a consumer-grade optical scanner (3D Systems, Sense). A 3D model of each patient was processed with mesh editing software (Autodesk, MeshMixer v2.9) before being exported as an STL file to software controlling the printer (Repetier-Host). A positive model of each face was printed using polylactic acid on a consumer-Grade 3D printer
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